Background: Previous investigations in pancreatic cancer suggested a prognostic role for secreted protein acidic and rich in cysteine (SPARC) expression in the peritumoral stroma but not for cytoplasmic SPARC expression. The aim of this study was to evaluate the impact of SPARC expression in pancreatic cancer patients treated with gemcitabine compared with untreated patients.
introduction
Pancreatic cancer still has to be considered as one of the most aggressive and devastating oncological diseases. New therapeutic options as the FOLFIRINOX [1] regimen and albumin-bound nab-paclitaxel [2] are emerging, but there is still a relevant and even raising mortality predicted for Europe in 2013 [3] . Also, relevant prognostic and predictive parameters are still lacking.
CONKO-001 was a randomized, controlled phase III trial investigating adjuvant therapy for patients with pancreatic cancer and established gemcitabine as standard adjuvant treatment [4] . Patients were randomized to receive either gemcitabine for 6 months or to observation only. The major finding was that gemcitabine delayed recurrence of disease for about 6 months and improved median overall survival (OS) and long-term survival [5, 6] Due to the fact that the trial includes a nontreated patient group compared with a chemotherapy group, it might be considered as an optimal starting point for translational research.
Only about 20% of patients present in resectable disease stages at the time of diagnosis. For these potentially curable cases, 5-year survival after adjuvant treatment is about 20%. Furthermore, translational research so far failed to define relevant predictive or prognostic biomarkers even though biomarkerbased personalization of patient care is already reality for a number of solid cancers [7] . Over decades, the research efforts in pancreatic cancer focused on tumor cells and their molecular pathways, but, recently, the role of the peritumoral stroma and tumor-stroma interactions became an increasing matter of interest [8] . The dense desmoplastic stroma is now well recognized to be one hallmark of the disease and considered a potential barrier against chemotherapy and thereby as one reasons for therapeutic resistance.
In this context, secreted protein acidic and rich in cysteine (SPARC) is of particular interest. SPARC has been described as being overexpressed in pancreatic cancer when compared with normal tissue and to be associated with aggressive tumor behavior [9] . Previous investigations in curatively resected pancreatic cancer suggested a negative prognostic role for high SPARC expression in the peritumoral stroma but not for the cancer cell cytoplasmic SPARC expression [10] .
Clinically even more important is the possibly predictive role of SPARC due to its interaction with the modified taxane nanoparticle albumin-bound (nab)-paclitaxel. In a phase I/II study in advanced pancreatic cancer, high SPARC expression was associated with a surprisingly long median OS in patients receiving a combination of nab-paclitaxel and gemcitabine in palliative first-line therapy [11] .
The significance of SPARC as a target and potential predictive factor for the efficacy of nab-paclitaxel (in combination with gemcitabine) is stressed by the positive results of a recently published phase III trial in metastatic pancreatic cancer confirming a benefit for the combination therapy of nab-paclitaxel and gemcitabine compared with gemcitabine alone [2] .
To our knowledge, there are no data from prospective clinical trials comparing the expression and prognostic impact of SPARC expression in patients who did not receive adjuvant chemotherapy compared with patients who received gemcitabine. The objective of our study was the evaluation of SPARC expression concerning its impact on survival in CONKO-001 patients treated with gemcitabine compared with nontreated patients. As peritumoral stroma and its constituents are believed to be critically involved in the delivery of cytotoxic drugs to cancer cells, the underlying hypothesis was that the prognostic impact of SPARC expression is restricted to patients receiving gemcitabine.
patients and methods
baseline data of CONKO-001 CONKO-001, a prospective randomized phase III study, investigated the role of adjuvant gemcitabine when compared with observation. Treatment with gemcitabine (1000 mg/m 2 d1, 8, 15, q29) was continued for 6 months in an outpatient setting; subsequent follow-ups were at 8 weekly intervals. In this open, multicenter randomized, controlled trial with an active treatment arm (adjuvant gemcitabine) and a control arm (observation only), a total of 368 patients with completely resected pancreatic cancer (R0 and R1 resection) were recruited between July 1998 and December 2004. The local pathologist made the diagnosis of pancreatic ductal adenocarcinoma. All cases were reevaluated by an experienced histopathologist before this study. Median disease-free survival (DFS) as the primary end point of the study was significantly improved by more than 6 months compared with observation only (13.4 versus 6.9 months, P < 0.001) [4] . OS was not significantly improved (22.1 versus 20.2 months) in the primary analysis, but in a re-evaluation after a longer follow-up time (22.8 versus 20.2 months, P = 0.01) [6] . The institutional review committee approved this study (trial registration isrctn.org Identifier: ISRCTN34802808).
SPARC immunohistochemistry
One hundred eighty-three tissue samples could be collect retrospectively, 160 samples were available for construction tissue microarrays (TMAs) and evaluation of SPARC expression. Diagnosis of ductal adenocarcinoma was confirmed before evaluation. Immunohistochemical staining for SPARC was carried out on TMAs according to standard procedures (clone 15G12; 1:100; Novocastra, Wetzlar, Germany). The antibody was tested for specific binding in vitro using western blotting. Each case was represented by three tissue cores of 1 mm in diameter from different tumor areas. The slides were digitalized (Mirax Scan, Zeiss, Jena, Germany) and evaluated by virtual microscopy using the VMScope Silde Explorer (VMScope, Berlin, Germany) by two observers (MS, BVS) blinded to clinical outcome and treatment arm. Concerning stromal SPARC, the intensity of staining was evaluated by a four-tier scoring system (negative, weak, moderate and strong). In parallel to SPARC, H&E-stained TMAs were evaluated to ensure that the evaluation of stromal SPARC excluded areas of smooth muscle fibers of the duodenal wall. Concerning cytoplasmic SPARC expression, the percentage of tumor cells with staining of the cytoplasm was evaluated (0% = '0', 1%-10% = '1', 11%-50% = '2', 51%-80% = '3', 81%-100% = '4'). The staining intensity was evaluated as negative (0), weak (1), moderate (2) or strong (3). The numeric values were multiplied, resulting in an immunoreactivity score (IRS) ranging from 0 to 12.
The cutoff point for stromal SPARC expression (strong versus <strong) was chosen based on the data distribution alone to avoid considerable differences of sample sizes without prior knowledge of clinical outcome. Strong stromal SPARC was defined as strong staining intensity. As cytoplasmic SPARC was measured with a wider range by a 0-12 point system, the cutoff point for cytoplasmic SPARC expression (high versus low) was determined original articles Annals of Oncology using an automated method as described earlier with the goal of optimization of prediction of DFS [12] . The definition for high cytoplasmic SPARC was IRS ≥3 (at least weak intensity in >50% of tumor cells or at least strong intensity in 1%-10% of tumor cells).
To reduce effects that might be caused by intratumoral heterogeneity, three different tumor areas were selected for the construction of TMAs. When different staining intensities were observed between the spots representing one case, the average was recorded and used for analysis. The reduce effects caused by intraobserver variability, TMAs were evaluated by two observers. Ambiguous cases were discussed to gain agreement.
statistical evaluation
DFS was defined as time from study entry to local or distant disease relapse, OS as time from study entry to death of any cause. The relation of SPARC expression with clinical and pathological tumor characteristics was evaluated using χ 2 tests. The Kaplan-Meier method with log-rank tests was used for univariable survival analyses. The Cox model was used for multivariable analysis [13] . In general, P values were calculated two sided and considered as significant when <0.05.
results
Cytoplasmic SPARC expression was detectable in 95 cases (59%), in which 65 (41%) were negative. Figure 1 illustrates exemplary cases. Stromal SPARC intensity was strong in 93 cases (58%), moderate in 58 (36%), weak in 8 (5%) and negative in 1 (<1%) (Figure 2A ). One hundred eighteen cases (74%) were defined as negative/low for cytoplasmic SPARC, 42 (26%) as high ( Figure 2B ). There was no association between stromal and cytoplasmic SPARC expression ( Figure 2C ). There was no statistically significant association between SPARC expression and clinical and pathological tumor characteristics (Table 1) . Despite a difference in regard to age at diagnosis (more patients >60 years in the gemcitabine group), both study arms were comparable in regard to clinical and pathological tumor characteristics (supplementary Table S1 , available at Annals of Oncology online). Figure 3 illustrates the survival analyses in dependence of SPARC expression. Strong stromal SPARC expression was associated with decreased patient DFS (strong versus not-strong staining intensity, 9.0 versus 12.6 months, P = 0.005) and OS (19.8 versus 26.6 months, P = 0.033). Stratified analysis according to treatment arm revealed that the effect was restricted to patients treated with gemcitabine. Patients who received gemcitabine had a shorter progression-free survival and OS when stromal SPARC was strong (DFS 12.1 versus 18.4 months; P = 0.007, OS 17.9 versus 30.2 months, P = 0.006). In the observation arm, there was no statistically significant association (DFS 6.6 versus 7.3 months, P = 0.767; OS 21.5 versus 18.2 months, P = 0.765). Cytoplasmic SPARC expression was also associated with worse patient outcome (high versus negative/ low, DFS 7.4 versus 12.1 months, P = 0.041; OS 14.1 versus 25.6 months, P = 0.011). Again, the effect was restricted to the treatment arm. Patients that received gemcitabine had a worse progression-free survival and OS when cytoplasmic SPARC was In multivariable survival analysis including stromal SPARC expression, treatment arm, pT stage, pN stage, tumor grade and resection margin status, stromal SPARC expression retained its prognostic impact on DFS as well as treatment arm and tumor grading. In a second step, the analysis was repeated including cytoplasmic instead of stromal SPARC expression and cytoplasmic SPARC retained its prognostic impact on DFS as well ( Table 2) .
discussion
In this study, we show that stromal and cytoplasmic SPARC expression are prognostic markers in pancreatic cancer patients treated with adjuvant gemcitabine after resection with curative intention, but not in patients that received no adjuvant therapy. To our best knowledge, this is the first evaluation of SPARC in a large randomized clinical trial including treated and untreated patients.
Our finding concerning stromal SPARC expression is in line with two immunohistochemical studies on 58 and 299 patients, respectively, that described stromal SPARC as a negative prognostic marker in pancreatic cancer [10, 14] . In addition, a study on 104 patients described SPARC mRNA expression to be associated with worse patient outcome [15] . The prognostic effect of cytoplasmic SPARC expression has not been described so far.
The strength of our study is the well-characterized study group with comprehensive follow-up data. In concordance with the ESPAC studies [16, 17] , the CONKO-001 study established adjuvant gemcitabine as standard of care in pancreatic cancer [4] and contributed to underline the important role of adjuvant therapy in pancreatic cancer [18] . Due to its prospective randomized phase III status and to the fact that the study can provide data for patients treated with adjuvant gemcitabine as well as for untreated patients, the CONKO-001 study is a unique and valuable resource for translational research.
A limitation might be the fact that only tissue samples from 183 of the initial 354 CONKO-001 patients were available for this study. One hundred sixty samples were suitable for construction of TMAs, the data regarding histopathological and clinical features of the subset are comparable with the overall study population of CONKO-001. However, the sample size may be considered as a limiting factor for statistical analysis, as for example pT and pN stages were not significantly related to DFS in multivariate analysis including stromal SPARC expression indicating a possible lack of power in the study. Another strength of our study is the straightforward and easyto-apply four-tier scoring system based on stromal SPARC staining intensity, as simple scoring systems might reduce the interobserver variability of immunohistochemistry.
SPARC belongs to the family of matricellular proteins that are associated with the structural components of the extracellular matrix. It is a collagen-binding protein that is involved in a variety of different functions as regulation of extracellular matrix composition, regulation of matrix metalloproteinases and modulation of growth factor signaling by interaction with soluble growth factors and cellular receptors [19] . The role of SPARC in cancer is complex and appears to be tissue and context specific. Experimental data in pancreatic cancer are conflicting [20] . SPARC derived from pancreatic stellate cells has been shown to increases the invasion of pancreatic cancer cells in vitro [14] . On the other hand, in mouse models of pancreatic cancer, SPARC −/− mice present with more aggressive tumors with altered extracellular collagen deposition, reduced apoptosis, reduced blood vessel density and an increase of immunosuppressive macrophages when compared with SPARC +/+ mice [21, 22] . SPARC has also been shown to be frequently lost in pancreatic cancer cells by hypermethylation [23, 24] . The treatment of pancreatic cancer cells with secreted SPARC derived from fibroblasts has been shown to have tumorsuppressive functions [23] .
One of the most interesting clinical aspects of SPARC is its potential role as a predictive marker for response to treatment with nab-paclitaxel. nab-Paclitaxel is a nanoparticle-sized albumine-bound taxane, initially developed to reduce taxaneassociated toxicities. It is approved for second-line therapy in advanced breast cancer [25] and very recently for metastatic pancreatic cancer in combination with gemcitabine.
In preclinical mouse models, nab-paclitaxel leads to increased antitumor activity and higher intratumoral taxane-concentrations when compared with conventional taxane formulations [26] . In a mouse model of pancreatic cancer, the combination of nab-paclitaxel with gemcitabine increases the intratumoral concentration of gemcitabine by inhibition of gemcitabine metabolism by cytidine deaminase [27] .
In patients treated with nab-paclitaxel for head and neck squamous cell cancer, the response was higher in SPARC positive tumors [28] . In breast cancer treated with nab-paclitaxel, the predictive value of SPARC is currently evaluated prospectively in the GeparSepto neoadjuvant trial (NCT01583426).
Von Hoff et al. investigated the significance of stromal SPARC expression in the context of a dose-finding phase I/II study including 37 patients for the combination of first-line nab-paclitaxel with gemcitabine. In this palliative trial, patients with a high SPARC expression treated by the combination therapy had a better outcome when stromal SPARC was high with an impressing median OS of about 18 months compared with 8 months in patients with a low SPARC expression. An additional experimental study could demonstrate higher gemcitabine levels in tumors pretreated with nab-paclitaxel and a depletion of the desmoplastic stroma. The improvement of clinical outcome may therefore not only be the effect of direct anticancer cell mechanisms of nab-paclitaxel, but additionally of targeting SPARC in the peritumoral stroma [11] .
Current data of a randomized phase III trial confirmed the efficacy of nab-paclitaxel in combination with gemcitabine in the palliative first-line therapy (von Hoff, NEJM 2013). Data on SPARC expression are not available so far.
Our study underlines the important role of SPARC expression in pancreatic cancer. As a new finding, the study demonstrates that the prognostic impact of SPARC was restricted to patients who received adjuvant treatment with gemcitabine. For the patients in the observation group-that can provide data for the natural course of disease after resection and before recurrenceno difference was found for DFS or OS. The patients with strong stromal or cytoplasmic SPARC expression in the gemcitabine group had a similar poor OS compared with the patients of the observation group. These findings imply that stromal SPARC might impede the uptake of gemcitabine in pancreatic cancer and patients with high SPARC expression seem not to benefit from adjuvant gemcitabine in terms of an improved OS. This could be explained by altered diffusion of cytotoxic drugs in differentially composed tumor stroma [29] . Treatment with nab-paclitaxel might be an interesting approach as especially patients with high SPARC expression might benefit who seem to have a decreased response to gemcitabine. The predictive role of SPARC for response to nab-paclitaxel and gemcitabine should further be evaluated in clinical trials.
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